LONG-TERM OUTCOMES AND KEY POINTS IN CHEMOIMMUNOTHERAPY FOR RELAPSED/REFRACTORY NEUROBLASTOMA (SIOP 2026) - Oct 23, 2026 - Abstract #Shift 01 - 122; Pres time: Sep 16, 2026; Location: Exhibition Area; "When an adequate response was not achieved, prompt modifications of chemotherapy regimens combined with response assessments performed every three months were critical in our management approach.Although overall survival rates remain encouraging in R/R patients treated with chemoimmunotherapy,therapeutic options become increasingly limited in patients experiencing repeated events.Notably,in patients who relapsed after achieving remission with DB,re-administration of DB in combination with an alternative chemotherapy regimen enabled the achievement of a second"
IO biomarker • Neuroblastoma • Solid Tumor • ALK • MYCN
|
|
Emre Cecen1; Deniz Kizmazoglu1; Ceren Sarioglu2; Safiye Aktas3; Recep Bekis4; Handan Guleryuz Ucar2; Ahmet Celik5; Mustafa Olguner6; Ayse Demiral7; Serra Kamer8; Riza Cetingoz7; Dilek Ince1; Nur Olgun9
|